STARTRK-2  - Clinical trial • Breast Cancer Foundation NZ

Donate to save lives this Breast Cancer Awareness Month.

STARTRK-2 

Recruiting
Updated: January 17, 2020

This is an open-label, multicenter, global phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3 or ROS1 gene fusion.

Patients will be assigned to different baskets according to tumor type and gene fusion.

Lung cancer and colorectal cancer are the main tumours of interest, but breast cancer solid tumours will also be included.

For full trial information

Australia

Flinders Medical Centre, Adelaide
Austin Hospital, Melbourne
Newcastle Private Hospital, Newcastle
Liverpool Hospital, Sydney

Contact:

Austin Hospital: Kellie Connellan

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.